Table 1.
Demographic and clinical characteristics of our study sample at baseline
| Patients with diabetic macular edema (n = 54) | |
|---|---|
| Mean ± standard deviation | |
| Age (years) | 69.2 ± 7.6 |
| Duration of diabetes mellitus (years) | 15.9 ± 7.1 |
| HbA1c (%) | 7.2 ± 0.6 |
| Best-corrected visual acuity (letters) | 52.0 ± 13.4 |
| Best-corrected visual acuity (Snellen) | 20/80 |
| Central retinal thickness (μm) | 537.6 ± 174.9 |
| Intraocular pressure (mmHg) | 13.3 ± 1.4 |
| N (%) | |
| Gender | |
| Male | 35 (64.8) |
| Female | 19 (35.2) |
| Lens status | |
| Phakic | 14 (25.9) |
| Pseudophakic | 40 (74.1) |
| Diabetic retinopathy status | |
| Nonproliferative | 48 (88.9) |
| Proliferative | 6 (11.1) |
| Hypertension | 48 (88.9) |
| Hyperlipidaemia | 24 (44.4) |
| Previous treatment | |
| Intravitreal ranibizumab | 46 (85.2) |
| Intravitreal aflibercept | 7 (13) |
| Focal/grid laser | 7 (13) |
| Duration of macular edema | |
| < 6 months | 25 (46.3) |
| ≥ 6 months | 29 (53.7) |